165735-63-7

Usage

Uses

Used in Pharmaceutical Research:
1-benzofuran-3-ylMethanaMine is used as a research compound for the development of potential drugs targeting neurological and psychiatric disorders. Its psychoactive properties make it a promising candidate for further investigation and development in this field.
Used in Organic Chemistry:
In the field of organic chemistry, 1-benzofuran-3-ylMethanaMine serves as a valuable intermediate or building block for the synthesis of more complex organic molecules. Its unique structure and reactivity contribute to the creation of novel compounds with potential applications in various industries.

Upstream product

• 391858-97-2 benzofuran-3-carboxaldehyde oxime 
• 959304-51-9 benzofuran-3-carboxamide 
• 4687-25-6 1-benzofuran-3-carbaldehyde 
• 4687-23-4 3-hydroxymethylbenzofuran 
• 201804-71-9 benzo[b]furan-3-ylmethyl azide 
• 4687-24-5 benzofuran-3-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Virtual Screening Approach to Identifying a Novel and Tractable Series of Pseudomonas aeruginosa Elastase Inhibitors

Novel therapies are required to treat chronic bacterial infections in cystic fibrosis (CF) sufferers. The most common pathogen responsible for these infections is Pseudomonas aeruginosa, which persists within the lungs of CF sufferers despite intensive antibiotic treatment. P. aeruginosa elastase (also known as LasB or pseudolysin) is a key virulence determinant that contributes to the pathogenesis and persistence of P. aeruginosa infections in CF patients. The crucial role of LasB in pseudomonal virulence makes it a good target for the development of an adjuvant drug for CF treatment. Herein we discuss the discovery of a new series of LasB inhibitors by virtual screening and computer assisted drug design (CADD) and their optimization leading to compounds 29 and 39 (Ki = 0.16 μM and 0.12 μM, respectively).

Design, synthesis, and evaluation of potential inhibitors of brassinin glucosyltransferase, a phytoalexin detoxifying enzyme from Sclerotinia sclerotiorum

Sclerotinia sclerotiorum is a fungal pathogen, which causes stem rot in crucifer crops and in several other plant families resulting in enormous yield losses all over the world. Brassinin is a phytoalexin produced by crucifer plants as part of a general d

CHEMICAL COMPOUNDS AS ANTIBIOTICS

The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p? q, L, ?, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.

BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY

The present invention relates to benzofuran ureas or carbamates of formula I and heteroaromatic analogues thereof as described below or a tautomer or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing these compounds, and to these compounds for use in therapy, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization. Formula (I) wherein X1 is CR1 or N; X2 is CR2 or N; X3 is CR3 or N; X4 is CR4 or N; with the proviso that at most two of X1, X2, X3 and X4 are N; E1 is O or NR6a; E2 is O or NR6b;with the proviso that E1 and E2 are not simultaneously O; L1 is a bond, optionally substituted C1-C6-alkylene or C3-C8-cycloalkylene; L2 is a bond, optionally substituted C1-C6-alkylene, C3-C8-cycloalkylene, etc.; A is 3-, 4-, 5-, 6-, 7- or 8-membered saturated, partially unsaturated or maximally unsaturated carbocyclic ring or a 3-, 4-, 5-, 6-, 7- or 8- membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring; or L2-A forms a group C1-C6-alkylene-OR13, C1-C6--alkylene-SR14 or C1-C6-alkylene-NR15R16; and R1, R2, R3, R4, R5, R6a, R6b, R13, R14, R15 and R16 are as defined in the claims and the description.

Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity

CrtN has been identified as an attractive and druggable target for treating pigmented Staphylococcus aureus infections. More than 100 new compounds were synthesized, which target the overwhelming the defects of the CrtN inhibitor 1. Analogues 23a and 23b demonstrated a significant activity against pigmented S. aureus Newman and 13 MRSA strains (IC50 = 0.02-10.5 nM), along with lower hERG inhibition (IC50 > 30 μM, ～10-fold decrease in comparison with 1). Furthermore, 23a and 23b were confirmed to reduce the staphylococcal load in the kidney and heart in a mouse model with normal treatment deeper than pretreatment ones, comparable even with vancomycin and linezolid. Remarkably, 23a could strongly block the pigment biosynthesis of these nine multidrug-resistant MRSA strains, including excellent activity against LRSA strains and VISA strains in vivo, and all of which demonstrated that 23a has a huge potential against intractable MRSA, VISA, and LRSA issues as a therapeutic drug.

Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder

The present invention is a method for the treatment of mania and/or bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as her

Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression

The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined. The pr

USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN

The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined. The present

USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS

The present invention is a methods for neuroprotection, for treating an acute neurodegenerative disorder, for treating a chronic neurodegenerative disorder and/or for preventing neuron death or damage following brain, head and/or spinal cord trauma or inj

USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION

The present invention is a method for the treatment of substance abuse and/or addiction comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as